Introduction
============

While age represents the greatest risk for developing AD, modern lifestyle which frequently leads to obesity and T2D also appears to increase risk for developing AD ([@B4]). While the link between T2D and AD may be equivocal (see [@B56]) and awaits longitudinal studies in humans that use new imaging technologies such as positron emission tomography (PET; see [@B2]), evidence exists for an association between perturbed insulin signaling and AD histopathology, namely, Aβ aggregates and Tau protein-containing neurofibrillary tangles (NFT) ([@B14]; [@B40]; [@B2]). The latter, complement reports that animal models of diabetes exhibit cognitive impairments and features of AD neuropathology ([@B12]). Together, these data make it plausible that AD may be amenable to antidiabetic treatments (for review, see [@B17]).

Insulin insensitivity, a mainstay of T2D, can be treated by activating PPARγ with TZD such as Pio ([@B1]). Various TZD have also been shown to improve cognition in AD patients and mouse models of the disease ([@B45]; [@B18]; [@B36]; [@B50]; [@B1]). However, mechanisms through which TZD exert their effects in the brain remain elusive. In support of previous reports ([@B38]; [@B35]; [@B60]), we recently mapped the expression of functional PPARγ in the rodent brain ([@B43]; [@B37]) and demonstrated the presence of TZD-responsive substrate(s) in the brain. Among other brain areas, PPARγ were localized in the frontal cortex and hippocampus, two cognitive centers that are particularly susceptible to neurodegeneration in AD.

In contrast to earlier views that aggregated Aβ and Tau are responsible for cognitive dysfunction in AD, recent work implicates soluble Aβ and hyperphosphorylated Tau protein as triggers of synaptic dysfunction and loss. Since synaptic malfunction and loss correlates strongly with cognitive deficits in AD patients ([@B59]; [@B39]), a better understanding of the pathophysiology of soluble Aβ and hyperphosphorylated Tau is imperative. While our own early studies showed that soluble Aβ causes synaptic degradation ([@B48], [@B47]; [@B31]; [@B9]), the role of Tau and its abnormal hyperphosphorylation in synaptic dysfunction is gaining increasing attention ([@B28]; [@B25]; [@B32]). An important impetus for this shift in focus was the demonstration that Tau, usually considered to be an axonal protein ([@B30]), is localized in dendrites ([@B21]; [@B25]) and that, in fact, Tau can be *de novo* synthesized and hyperphosphorylated in dendrites and spines ([@B16]; [@B42]; [@B29]).

The *in vitro* studies reported here focused on whether, and how, activation of PPARγ can influence the synaptotoxic effects of Aβ and/or Tau. Our experiments show that Pio-activated neuronal PPARγ inhibits APP misprocessing and protects against Aβ-induced synaptic degradation. In addition, the PPARγ agonist attenuated Tau missorting and hyperphosphorylation in Aβ-exposed neurons.

Materials and Methods {#s1}
=====================

Drugs
-----

Soluble Aβ~1--42~ was prepared from peptide obtained from American Peptide Co. (Sunnyvale, CA, United States; Cat. \#62-0-80), according to [@B48] and [@B53] and used at a concentration of 1 μM. Pio (Pio, 10 μM) and GW9662 (1 μM), both purchased from Sigma-Aldrich (Taufkirchen, Germany) were used after solution in dimethylsulfoxide (DMSO; final DMSO concentration 0.01%). Doses of Pio were chosen on the basis of previous cell culture studies ([@B22]; [@B8]).

Cell Culture
------------

The human neuroblastoma cell line, SH-SY5Y \[American Tissue Culture Collection (ATCC^®^), CRL-2266^TM^, Germany\] was cultured in Minimum Essential Medium with Glutamax^®^, supplemented with 10% FCS, 1% penicillin-streptomycin, and 2 mM L-glutamine. When ∼ 20% confluent (6 × 5^10^ cells/well of a 6-well plate), cells were differentiated with 50 μM retinoic acid (Sigma-Aldrich) in 1% FCS medium for 5 days, followed by 20 ng/ml nerve growth factor (NGF; Bio-Techne, Wiesbaden, Germany) for a further 5 days. Cells were maintained at 37°C in an incubator with 5% CO~2~ and 95% relative humidity.

Primary Neural Cell Cultures
----------------------------

Primary frontocortical and hippocampal cultures were prepared from brains of CD1 mice aged 5 days, according to previously described protocols ([@B34]; [@B48]). For molecular/biochemical analyses, cells were plated on gelatine/poly-D-lysine-coated plates and maintained in Neurobasal/B27 medium supplemented with basic fibroblast growth factor (10 ng/ml; Life Technologies (Eggenstein, Germany) and kanamycin (100 μg/ml; Life Technologies). For immunocytochemical analyses, cells were plated at a density of 400--500 cells/mm^2^ on poly-D-lysine-coated glass coverslips ([@B62]), and grown in Neurobasal/B27 before use after 14 days *in vitro* (14 DIV). Cultures were comprised of 15--20% of mature \[microtubule-associated protein 2 (MAP2)-positive\] neurons, 20--25% of astrocytes \[glial acidic fibrillary acidic protein (GFAP)-positive\], and ∼1% of O4-positive oligodendrocytes; microglia (anti-CD68, -CD1b and -Iba1 labeled) were undetectable. Experiments adhered to European Union Council Directive (2010/63/EU) and local regulations on use of animals.

Cell Viability Assay
--------------------

The MTS assay kit (CellTiter 96^®^ AQueous One Solution Cell Proliferation Assay (Promega, Mannheim, Germany) was used to monitor cell viability, following the manufacturer's instructions. Briefly, after exposure to MTS solution (3 h in dark), the optical density (490 nm) of the supernatant was measured in an ELISA reader (BioTek Instruments, Winooski, VT, United States).

Immunofluorescence Staining and Image Analysis
----------------------------------------------

Cells were stained as described by [@B48]. Briefly, cells were fixed in ice-cold 4% paraformaldehyde for 15 min, washed in PBS (3 × 5 min) before permeabilization with 0.1% Triton X-100 (30 min), and blocked in 10% FCS (30 min, RT). Primary and secondary antibody solutions were prepared in 0.01 M PBS containing 0.1% Triton X-100 and 10% FCS. Cells were incubated (16 h; 4°C), with primary antibodies against postsynaptic density-95 (PSD-95; 1:1000; Neuromab, Davis, CA, United States; \#75-028), synapsin 1,2 (1:1500; Synaptic Systems, Göttingen, Germany; \#16002), and/or pTau (pS396-Tau) (1:1000; abcam, Cambridge, United Kingdom; ab109390) in PBST (0.01 M PBS + 0.03% Triton X100). After washing (3 × 30min in 0.01 M PBS), cells were incubated with one of the following secondary antibodies, as appropriate: goat-anti-rabbit Alexa Fluor 488 (1:1000; Invitrogen, Eggenstein, Germany; \# A110374) or goat-anti- mouse Alexa Fuor 594 (1:1000; Invitrogen; \# A110029)\] for 1 h at RT; nuclei were counterstained with followed by Hoechst dye 33341 (Sigma; 1:50000; 10 min, RT). Images were obtained using a laser scanning confocal microscope (Olympus Fluoview 1000, Hamburg, Germany). For image quantification, 100 cells in 5 separate fields on each coverslip (3--6 coverslips per condition) were analyzed. The number of stained puncta on a defined dendritic length (100 μm) were quantified using SynPAnal software to monitor synaptic density ([@B13]).

Immunoblotting
--------------

Cells were homogenized in lysis buffer \[10 mM HEPES pH 7.9, 150 mM NaCl, 1 mM EGTA, 10% glycerol, 1% NP-40, Complete Protease Inhibitor (Roche, Mannheim, Germany), Phosphatase Inhibitor Cocktails II and III (Sigma)\] using a sonifier (5 pulses, 20 kHz). After centrifugation (14,000 ×*g*; 20 min), the protein content of the lysates (supernatants) were determined by the Lowry assay ([@B33]); spectroscopic measurements (absorption wavelength: 750 nM) were made with a Synergy-HT plate reader (BioTek Instruments, Winooski, VT, United States). Sodium dodecyl sulfate-polyacrylamide gel (10%) electrophoresis (SDS-PAGE) was used to resolve heat-denatured (95^o^ C; 10 min) protein lysates (30 μg). After electrophoresis, proteins were transferred onto 0.2 μm nitrocellulose membranes (BioRad, Hercules, CA, United States) by Turbo Transfer (BioRad). Transfer quality was assessed by incubating with Ponceau-S solution. Membranes were subsequently blocked in 5% non-fat milk or 5% BSA in TBS-T (1 h, RT), before overnight incubation (4^o^C) with one of the following primary antisera: APP A4 (1:500; Millipore, Burlington, MA, United States; \#MAB348), BACE (D105E5) (1:1000; Cell Signaling; \#5606), nicastrin (1:1000; Sigma; \#N16660), pS202-Tau (1:1500; Abcam; ab108387); pT205-Tau (1:1500; Abcam; ab4841), pT231-Tau (1:1500; Abcam; ab151559), pS356-Tau (1:1500; Abcam; ab92682), PHF1 (p396/404-Tau; 1:1000; kind gift form Dr. Peter Davies, New York, NY, United States), Tau5 (1:1500; Abcam; ab 80579), GluN2B (1:1000, Abcam 65783), pSer9-GSK3β and total GSK3β (1:1000, Cell Signaling) and either actin (1:2500; Chemicon/Fischer Scientific, Munich, Germany; \#MAB1501R) or GAPDH (1:1500, Abcam; ab8245). After thorough washing, membranes were incubated with a corresponding horseradish peroxidase (HRP)-conjugated secondary antibody \[goat anti-rabbit (1:1000; Fischer Scientific; \#31460) or goat anti-mouse (1:2000; BioRad; 170-6516)\] for 1 h (RT). Clarity^TM^ Western ECL reagent (Biorad) was used to visualize (ChemiDoc MP Imaging System; BioRad) and quantify (ImageLab 5.1 Software from BioRad) proteins.

PCR Analysis
------------

Total RNA was isolated from cell lysates using the NucleoSpin (RNA) kit (Macherey-Nagel, Duren, Germany) and RNA concentrations were determined with a NanoPhotometer (SmartSpec^TM^ Plus, Biorad).

Reverse Transcription
---------------------

Complementary DNA (cDNA) was prepared from 1 μg RNA using a RevertAid RT Reverse Transcription kit (Thermo Scientific) with an oligo deoxythymine (dT) primer. Polymerase chain reactions (PCR) were performed using Taq DNA Polymerase kits (Fermentas/ThermoFisher) and the following primers:

1.  *ABCA1*: fwd 5′-GACATCCTGAAGCCAATCC-3′

2.  rev 5′-GTAGTTGTTGTCCTCATACC-3′

3.  *PGC-1α*: fwd 5′-CGTGTCGAGACTCAGTGTC-3′

4.  rev 5′-GTGTCTGTAGTGGCTTGATTC-3′

5.  GAPDH: fwd 5′-CCATCACCATCTTCCAGG-3′

6.  rev 5′-GTTGAAGTCGCAGGAGACAAC-3′

The PCR products were quantified using a Roche LightCycler 96. Relative expression levels of target genes were computed according to Pfaffl (2001).

Statistical Analysis
--------------------

Statistical analysis and graphic representations were performed using GraphPad Prisma software (GraphPad, San Diego, United States). Numerical data were analyzed by 1-way ANOVA or Kruskall-Wallis tests, and *post hoc* tests, as appropriate. Values were considered significant when *p* \< 0.05.

Results
=======

Activation of PPARγ Attenuates APP Misprocessing, Tau Accumulation and Aβ-Induced Neurotoxicity in Differentiated SHSY5Y Cells
------------------------------------------------------------------------------------------------------------------------------

Initially, we examined whether differentiated human SH-SY5Y cells express functional PPARγ. For that purpose, we monitored the expression of two PPARγ target genes, *peroxisome proliferator-activated receptor gamma coactivator 1-α (PGC-1*α*)* and *ABCA1* ([@B54]; [@B26]) after treating cells with the potent PPARγ agonist, Pio (10 μM; 24 h). As shown in [Supplementary Figure 1](#SM1){ref-type="supplementary-material"}, Pio induced the expression of the mRNA levels of *PGC-1*α and *ABCA1*. These effects were abolished when cells were co-treated with Pio and the PPARγ antagonist GW9662, indicating that the actions of Pio were mediated by endogenous PPARγ ([Supplementary Figure 1](#SM1){ref-type="supplementary-material"}).

The neurodegenerative cascade leading to AD is initiated by Aβ. Here, to examine the role of PPARγ in modulating neuropathological markers of AD, we exploited our previously described model in which Aβ was shown to increase misprocessing of APP ([@B7]). Western blot analysis revealed that treatment of cells with Aβ (1 μM; 24 h) upregulated APP levels ([Figure 1A,E](#F1){ref-type="fig"}) as well as those of β-secretase (BACE1) ([Figure 1B,E](#F1){ref-type="fig"}) and nicastrin ([Figure 1C,E](#F1){ref-type="fig"}) which sequentially contribute to the generation of Aβ. It may be extrapolated from these observations that exogenous Aβ stimulates the misprocessing of APP into Aβ. Importantly, concomitant exposure with Pio abolished the ability of Aβ to increase the expression of APP, BACE1 and nicastrin protein ([Figure 1A--C,E](#F1){ref-type="fig"}).

![Pioglitazone (Pio) attenuates APP misprocessing, Tau accumulation and Aβ-induced neurotoxicity in differentiated SHSY5Y cells.Exposure to Aβ (1 μM, 24 h) upregulated the levels of APP (*p* \< 0.0001) **(A,E)**, BACE-1 (*p* = 0.002) **(B,E)**, and nicastrin (*p* = 0.003) **(C,E)**; co-treatment with the PPARγ agonist, Pio (Pio; 10 μM) abolished these effects of Aβ (*p*~APP~ \< 0.0001; *p*~BACE~ = 0.001; *p*~nicastrin~ = 0.038). Exposure to Aβ increased total Tau levels (*p* = 0.002) in a Pio-reversible manner (*p* = 0.006) \[1-way ANOVA *F* = 7.745; *p* = 0.001\] **(D,E)**. Treatment of cells with Aβ resulted in elevated levels of pS396/404-Tau (*p* = 0.015) in a Pio-reversible manner (*p* = 0.029) \[1-way ANOVA *F* = 5.551; *p* = 0.015\] **(F,E)**; Aβ also reduced levels of pSer9-GSK3β (inactive GSK3β; (*p* = 0.029) **(G,E)**. Co-treatment of cells with Aβ and Pio failed to show Aβ-driven elevation of GluN2B protein levels (*p* = 0.023) \[1-way ANOVA *F* = 7.553; *p* = 0.0027\] **(H)** and Aβ-stimulated cell death (*p* = 0.008) \[1-way ANOVA *F* = 6.113; *p* = 0.007\] **(I)**; *N* = 3-5/condition; different cell cultures. All numeric data represent means ± S.E.M.](fncel-13-00239-g001){#F1}

Growing appreciation of the neurotoxic role of Tau protein ([@B55]; [@B44]; [@B24]) prompted an examination of how Aβ, in the presence or absence of Pio (10 μM), influences Tau metabolism in differentiated SH-SY5Y cells. As shown in [Figure 1D,E](#F1){ref-type="fig"}, immunoblot analysis revealed that incubation of cells with Aβ results in increased levels of total Tau, an effect blocked when cells were co-treated with Pio. Further, Aβ treatment increased Tau phosphorylation (pS396/404-Tau) ([Figure 1F](#F1){ref-type="fig"}) while decreasing the amount of inactive (pSer9) GSK-3β ([Figure 1G](#F1){ref-type="fig"}); the effects of Aβ on pTau were also reversed by Pio ([Figure 1E--G](#F1){ref-type="fig"}). In addition, we monitored the levels of NR2B subunit of the glutamate (NMDA) receptor (GluN2B) which is strongly implicated in neurotoxicity. Consistent with previous evidence that GluN2B largely mediate the neurotoxic actions of Aβ and Tau ([@B25]), we observed that Aβ elevate GluN2B levels ([Figure 1H,E](#F1){ref-type="fig"}) and, at the same time, compromises cell viability ([Figure 1I](#F1){ref-type="fig"}). Both of these Aβ-induced phenomena were blocked when cells were co-treated with Pio, although Pio *per se* did not have any effect, i.e., Pio did not exert any effect in the absence of Aβ ([Supplementary Figure 2](#SM1){ref-type="supplementary-material"}).

Synaptic Degradation Induced by Aβ in Primary Neuronal Cultures Is Blocked by Pio Treatment
-------------------------------------------------------------------------------------------

Since both Aβ and hyperphosphorylated Tau are known to disrupt synaptic function, we next examined the potential of Pio to prevent Aβ-driven synaptotoxicity in differentiated cultures derived from mouse frontal cortex and hippocampus; cultures were used at DIV 14, when 15--20% of the cells are MAP2-positive (mature neurons) bearing synapsin 1,2-immunoreactive mature synapses. Both frontocortical and hippocampal cultures express transcriptionally active PPARγ and display similar responses to Aβ ([@B37]). As shown previously ([@B48]; [@B31]), synaptic loss was assessed by counting (SynPal software) apposed postsynaptic PSD-95- and presynaptic synapsin 1, 2- immunoreactive elements in confocal images ([Figure 2A](#F2){ref-type="fig"}).

![Aβ-induced synaptic loss is rescued by Pio treatment. **(A)** Representative confocal images of synapses (identified by apposed PSD-95-, *green*, and synapsin-*, red*, immunoreactive elements) in mouse primary neuronal cultures under control conditions and exposure to Aβ (1 μM, 24 h) alone Aβ + Pio (Pio, PPARγ agonist). Examples of apposed PSD-95- and synapsin-positive staining are marked with white arrows. **(B)** Puncta analysis of dendrites revealed that Aβ decreases the density of PSD-95 puncta (*p* \< 0.0001 vs. control) and that Pio reverts the effects of Aβ (*p* \< 0.0001) \[1-way ANOVA, *F*~2,63~ = 35.01; *p* \< 0.0001\]. **(C)** The reduced number of synapsin-positive puncta after Aβ treatment were restored to control levels when cells were co-exposed to Pio (*p* = 0.001) \[1-way ANOVA, *F*~2,63~ = 10,68; *p* \< 0.0001\]. **(D)** Synapses, doubled-labeled for PSD-95 and synapsin immunoreactivity, were reduced after treatment with Aβ (*p* = 0.0003), indicating synaptic degradation and loss. The latter was absent in cells exposed to both Aβ and Pio (*p* = 0.0012) \[1-way ANOVA, *F*~2,63~ = 10.32; *p* \< 0.0001\]; *N* = 15 non-overlapping fields/condition; different cultures, Means ± S.E.M are shown. Scale bar: 10 μm.](fncel-13-00239-g002){#F2}

Neurons exposed to Aβ showed fewer synapses (reduced PSD-95 and synapsin puncta density ([Figure 2A--D](#F2){ref-type="fig"}). This result is consistent with previous findings by [@B48] and [@B31]. Interestingly, the synaptic loss caused by Aβ was blocked in the presence of the PPARγ agonist Pio ([Figure 2A--D](#F2){ref-type="fig"}), suggesting that Pio protects against Aβ synaptotoxicity.

Pioglitazone Counteracts Aβ-Driven Tau Hyperphosphorylation in Primary Cultures
-------------------------------------------------------------------------------

In light of the fact that (i) Aβ induces Tau hyperphosphorylation ([@B55]; [@B52]), (ii) Tau hyperphosphorylation is causally linked to synaptic dysfunction and loss ([@B28]), and (iii) Pio reduces the cytotoxic actions of Aβ (cf. [Figure 1J](#F1){ref-type="fig"}), we also examined whether Pio can interfere with Aβ-triggered Tau hyperphosphorylation by monitoring drug effects on different phospho-epitopes of Tau (around and within its microtubule-binding domain) (see [Figure 3A](#F3){ref-type="fig"}).

![Pioglitazone (Pio) counteracts Aβ-driven Tau hyperphosphorylation. **(A)** Schematic representation of Tau protein and the different phosphorylation epitopes analyzed in this study. (**B--G)** Effects of Aβ (1 μM, 24 h), in presence and absence of Pio (Pio; 10 μM), on the expression of different forms of pTau in 14 DIV primary neurons. Representative immunoblots are shown in **(F)**. Semi-quantitative analysis reveals that, as compared to vehicle treatment, Aβ induces higher levels of pS202-Tau **(B)**, pT205-Tau **(C)**, pT231-Tau **(D)**, pS356-Tau **(E)** and pS396/404-Tau **(G)** (*p* \< 0.05 in all cases); all of these effects were attenuated (*p* \< 0.05) when cells were co-treated with Pio **(B--G)** \[Kruskal-Wallis test *H*~2~ = 9.881, *p* = 0.0002\]; *N* = 3-5/condition; different cell cultures. Semi-quantitative data are shown as means ± S.E.M.](fncel-13-00239-g003){#F3}

Our analysis revealed that exposure of primary neurons to Aβ leads to increased levels of various forms of pTau (pSer202-Tau, pThr205-Tau, pThr231-Tau, pSer356 and pSer396/Ser404), as shown in [Figure 3F](#F3){ref-type="fig"} (representative immunoblots) and [Figure 3B--G](#F3){ref-type="fig"} (semi-quantitative data). Notably, although Pio alone did not exert any effect on Tau protein ([Supplementary Figure 2](#SM1){ref-type="supplementary-material"}), the PPARγ agonist blocked Aβ-upregulated levels of pSer202-Tau, pThr205-Tau, pThr231-Tau, pSer356 and pSer396/Ser404-Tau ([Figure 3A--G](#F3){ref-type="fig"}).

Prevention of Aβ-Induced Synaptic Missorting of Tau by Pio
----------------------------------------------------------

Whereas Tau protein expression is confined to axons under normal conditions ([@B30]), increased levels of Aβ have been shown to re-direct Tau into dendrites and dendritic spines, via a process termed "missorting" which triggers synaptic loss ([@B25]; [@B64]). Having observed that Pio exhibits a protective effect against Tau hyperphosphorylation (see [Figure 3](#F3){ref-type="fig"}), we next monitored the effect of Pio on the localization of pTau (specifically, pSer396-Tau) in dendrites and synapses.

As shown in [Figure 4](#F4){ref-type="fig"}, treatment of neuronal cultures with Aβ was found to increase p-Tau immunoreactivity in dendritic puncta ([Figure 4A,B](#F4){ref-type="fig"}). The latter was abrogated when cultures were simultaneously exposed to Pio ([Figure 4A,B](#F4){ref-type="fig"}). More detailed analysis of the data, in which the number of PSD-95/synapsin-positive synapses labeled with pTau were quantified, confirmed that Pio can effectively prevent the Aβ-induced mislocalization of pTau in PSD-95/synapsin-positive puncta ([Figure 4C](#F4){ref-type="fig"}). Note that, Pio itself did not display activity on any of the synaptic parameters monitored ([Supplementary Figure 3](#SM1){ref-type="supplementary-material"}).

![Prevention of Aβ-driven synaptic missorting of phospho-Tau by Pio. **(A)** Representative immunofluorescent images of 14 DIV neurons stained with antibodies against pTau (pSer396-Tau, *red*) and PSD-95 (*green*) after treatment with Aβ (1 μM, 24 h) and/or Pio (10 μM). Examples of apposed PSD-95- and pTau-positive staining are marked with white arrows. **(B)** Density of pTau-positive puncta in dendrites increases after exposure to Aβ (*p* \< 0.0001 vs. control) in a Pio-reversible fashion (*p* = 0.0002 vs. Aβ alone) \[1-way ANOVA, *F*~2,44~ = 18.02; *p* \< 0.0001\]. **(C)** The percentage of PSD-95-labeled synaptic puncta that are pTau-positive is higher in Aβ- vs. vehicle-treated cells (*p* = 0.0002), indicating missorting of pTau to synapses. In the presence of Pio, Aβ exhibited a weaker effect on pTau missorting (*p* = 0.002) \[1-way ANOVA, *F*~2,76~ = 11.79; *p* \< 0.0001\]; *N* = 15 non-overlapping fields/condition; different cultures. Means ± S.E.M. are depicted. Scale bar: 10 μm.](fncel-13-00239-g004){#F4}

Since the results described in [Figure 1](#F1){ref-type="fig"}--[4](#F4){ref-type="fig"} clearly indicate involvement of PPARγ in regulating APP and Tau metabolism, as well as neuronal survival, we considered it important to investigate whether the interruption of Aβ-induced synaptic loss and mislocalization of pTau by Pio depends on PPARγ. To this end, primary neurons were pre-treated with the PPARγ antagonist GW9662 before exposure to Pio + Aβ. Indeed, as shown in [Figure 5A--C](#F5){ref-type="fig"}, PPARγ were demonstrated to mediate the reversal of Aβ-induced missorting of Tau to dendritic spines by Pio: the protective potency of Pio was lost in GW9662-treated cells. Briefly, the percentage of pTau-labeled synapses was greater in Pio + Aβ-treated cells than in cells receiving the combination of GW9662, Pio and Aβ ([Figure 5B](#F5){ref-type="fig"}). Similarly, on the basis of PSD-95 puncta density measurements, GW9662 was found to neutralize the rescuing effect of Pio on Aβ-driven synaptic loss ([Figure 5C](#F5){ref-type="fig"}). Together, this set of data demonstrates that PPARγ mediate the rescuing actions of Pio against Aβ-triggered synaptotoxity by preventing the missorting of Tau to synapses.

![Protective actions of Pio against Aβ-induced missorting of Tau and synaptic loss are PPARγ-mediated. **(A)** Primary cultures were pre-treated with the specific PPARγ antagonist GW9662 (GW) before exposure to Aβ alone, or Aβ + Pio (PPARγ agonist). Cells were immunostained for PSD-95 (*green*) and pTau (pSer396-Tau; *red*) and examined by confocal microscopy. Examples of apposed PSD-95- and pTau-positive staining are marked with white arrows. **(B)** Shows that Aβ leads to an increase (*p* \< 0.0001) in the percentage of pTau-positive synaptic puncta (PSD-labeled), an effect blocked when Pio is also present. Importantly, Pio failed to counter the effects of Aβ when cells were pre-exposed to GW9662 (*p* \< 0.0001 in all cases) \[1-way ANOVA, *F*~3,37~ = 62.40; *p* \< 0.0001\]. **(C)** Shows that GW9662 also blocks the protective effects of Pio (*p* \< 0.0001) against the loss of PSD-95-positive puncta in neurons treated with Aβ (*p* = 0.0002) \[1-way ANOVA, *F*~3,48~ = 45.44; *p* \< 0.0001\]; *N* = 15 non-overlapping fields/condition. Numerical data shown represent means ± S.E.M. Scale bar: 10 μm.](fncel-13-00239-g005){#F5}

Discussion
==========

Pioglitazone, a pharmacological agonist of the nuclear receptor PPARγ, acts as an insulin sensitizer and is used to treat T2D, a risk factor for AD ([@B1]; [@B2]; [@B4]). Reports that Pio and other TZD improve cognitive performance in AD patients and in mouse models of the disease ([@B45]; [@B18]; [@B36]; [@B50]; [@B1]) suggest that PPARγ may be potential therapeutic targets in AD ([@B66]). A central question in the present work was whether the pro-cognitive and anti-neurodegenerative effects of Pio reflect direct actions in the brain or if they represent a collateral benefit of improved insulin sensitivity. Notably, some authors have also attributed the neuroprotective effects of TZD to their anti-inflammatory and/or -oxidative properties ([@B20], [@B19]; [@B57]; [@B65]), phenomena that could help explain the purported role of activated PPARγ in a spectrum of neurological diseases ([@B66]).

Complementing data reported by [@B61], we here show that Pio counteracts the detrimental effects of Aβ on neural cell viability. In addition, we found that Pio dampens Aβ-stimulated misprocessing of endogenous APP into Aβ through the mediation of β-secretase 1 (BACE1) and γ-secretase (see [@B7]). These observations are consistent with previous reports that TZD can reduce APP misprocessing as well as Aβ deposition in transgenic mouse models of AD ([@B15]; [@B36]; [@B51]) as well as in primary neural cultures ([@B36]; [@B51]) and in neural cell lines overexpressing APP ([@B5]). The inhibitory effect of Pio on APP misprocessing likely reflects transcriptional regulation of BACE1 by PPARγ: the *BACE1* promoter harbors a PPARγ response element (PPRE) ([@B20]; [@B49]; [@B11]; [@B58]) and genetic deletion of related PPAR isoforms (PPAR β/δ) leads to increased BACE1 expression in mice ([@B3]).

We also report here that Pio prevents the ability of exogenous Aβ to increase the expression of Tau and several phospho-Tau epitopes that are found in the brains of AD patients (see [@B23]). The latter observation, which is consistent with a previous report that TZD reduce Tau hyperphosphorylation in a 3 × Tg mouse model of AD ([@B63]), is important since Tau is now recognized as a critical mediator of the synaptotoxic effects of Aβ ([@B28]; [@B46]; [@B25]; [@B32]). Together, this and the previous set of data suggest that activation of PPARγ breaks the link between Aβ-induced neurotoxicity and tau pathology.

The present work also examined the possibility that PPARγ may be involved in synaptic dysfunction and loss, two events that appear to underpin memory loss in AD patients ([@B61]; [@B10]; [@B6]). In line with our previous findings in frontocortical ([@B48]) and hippocampal ([@B31]) neurons, Aβ was here found to induce a loss of synapses, seen as a reduction in the number of apposed synapsin- and PSD-95-immunoreactive puncta. Further, and in confirmation of results reported by [@B61], we show that Aβ-induced degradation of synapses can be blocked by co-treating neurons with Pio. Interestingly, earlier studies reported that TZD-activated PPARγ promote synaptic plasticity ([@B41]). Notwithstanding a role for neurotrophins in mediating the neuroplastic effects of activated PPARγ ([@B27]), analysis of the data presented in this paper suggest, for the first time, that PPARγ-mediated inhibition of Tau mislocalization (missorting) to the dendritic compartment represents an important mechanism through which TZD impede progression of the neurodegenerative cascade initiated by Aβ. In agreement with earlier reports ([@B21]; [@B64]), we observed that Aβ leads to an accumulation of hyperphosphorylated Tau in dendritic spines; the latter event is believed to activate a pathway that upregulates GluN2B receptor expression which, in turn, culminates in synaptic dysfunction and elimination ([@B21]; [@B25]; [@B32]). Briefly, our results indicate that Pio prevents Aβ-driven hyperphosphorylation and intraneuronal trafficking of Tau. It is important to note here that [@B21] demonstrated that hyperphosphorylation of Tau is necessary for the missorting and accumulation of Tau at synapses.

In summary, the current experiments provide new insights into the mechanisms through which activated PPARγ can provide neuroprotection by acting directly on neural substrates, independently of their insulin-sensitizing properties in the periphery. Interestingly, the protective actions of Pio only became manifest when neurons were challenged with an insult, namely, elevated Aβ levels. Lastly, this work introduces the notion that prevention of the mislocalization of Tau to dendrites is a key mechanism underlying the neuroprotective actions of PPARγ agonists.
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Aβ

:   amyloid β

ABCA1

:   ATP-binding cassette transporter ABCA1

AD

:   Alzheimer's disease

APP

:   amyloid precursor protein

BACE1

:   β-secretase 1

DIV

:   days *in vitro*

FCS

:   fetal calf serum

GFAP

:   glial acidic fibrillary protein \[GFAP\]

GluN2B

:   glutamatergic receptor 2B subunit

GSK-3β

:   glycogen synthase kinase 3β

PGC-1α

:   peroxisome proliferator-activated receptor gamma coactivator 1α

Pio

:   pioglitazone

PPARγ

:   peroxisome proliferator-activated receptor γ

PSD-95

:   postsynaptic density-95

p-Tau

:   phosphorylated tau

T2D

:   type 2 diabetes

TZD

:   thiazolidinediones.
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